New York State Common Retirement Fund Trims Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

New York State Common Retirement Fund decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,295 shares of the company's stock after selling 10,086 shares during the period. New York State Common Retirement Fund's holdings in Vaxcyte were worth $3,872,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Janus Henderson Group PLC raised its stake in shares of Vaxcyte by 23.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. RA Capital Management L.P. grew its position in shares of Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock valued at $992,914,000 after purchasing an additional 485,436 shares in the last quarter. State Street Corp grew its stake in Vaxcyte by 1.1% during the third quarter. State Street Corp now owns 3,405,743 shares of the company's stock valued at $389,174,000 after acquiring an additional 38,596 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock worth $315,162,000 after purchasing an additional 324,560 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Vaxcyte by 10.6% in the third quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company's stock worth $308,675,000 after buying an additional 259,010 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Remove Ads

Insider Activity

In other news, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $91.49, for a total value of $457,450.00. Following the completion of the sale, the senior vice president now directly owns 28,697 shares of the company's stock, valued at $2,625,488.53. This represents a 14.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 61,616 shares of company stock valued at $5,225,971 in the last ninety days. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Shares of Vaxcyte stock traded down $2.27 during trading on Tuesday, hitting $69.84. The company's stock had a trading volume of 630,442 shares, compared to its average volume of 1,142,867. The company has a fifty day simple moving average of $84.30 and a two-hundred day simple moving average of $94.91. The company has a market capitalization of $8.99 billion, a PE ratio of -15.29 and a beta of 0.98. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on PCVX shares. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Guggenheim reaffirmed a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte has a consensus rating of "Buy" and an average price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.